October 2023 - Page 4 of 16

Interview with Dr. Girard Deciphers at ELCC 2023

By Peter W. PENG 2023.10.24

The 2023 European Lung Cancer Congress (ELCC) was held from March 29th to April 1st, in a combined online and offline format in Copenhagen, Denmark. Professor Nicolas Girard from the Curie Institute in Paris, France, presented the 3-year data update (Abstract 84O) of the CheckMate 816 study on neoadjuvant immune combined with chemotherapy in the Proffered Paper 2 session. In an interview with Oncology Frontier he further discussed the significant research data released at ELCC 2023, the status of dual immune checkpoint inhibitor regimens in the treatment of driver gene-negative non-small cell lung cancer (NSCLC), and the treatment of EGFR exon 20 insertion mutations (ex20ins) subtype.

2023 SGBCC Expert Voting: Radiotherapy

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, known as the "City of Music", from March 15th to 18th, 2023, local time. SGBCC brought together breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics regarding early-stage breast cancer treatment. This culminates in the St.Gallen early-stage breast cancer international expert consensus, which is updated every two years. On the last day of the conference, the expert voting was the highlight.

2023 SGBCC Expert Voting: Endocrine Therapy and Chemotherapy Decision for ER-Positive Breast Cancer

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "World Music Capital," from March 15 to 18, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in early breast cancer diagnosis and treatment, forming an updated St.Gallen International Expert Consensus on Early Breast Cancer every two years. On the final day of the conference, expert voting took center stage. Oncology Frontier has compiled expert votes on two topics: adjuvant endocrine therapy and chemotherapy decisions for ER-positive breast cancer.

2023 SGBCC Expert Voting: Pathology, Genes, DCIS, Male Breast Cancer

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music", from March 15 to 18, 2023 local time. SGBCC gathered breast cancer opinion leaders from all over the world to discuss and vote on the most cutting-edge and controversial topics related to early-stage breast cancer treatment. This forms the St.Gallen Early Breast Cancer International Expert Consensus, which is updated every two years. "Oncology Frontier" has compiled expert votes on topics related to early breast cancer's pathology, genes, DCIS, and male-related issues. Let's experience the St.Gallen atmosphere of early breast cancer treatment decision-making.

2023 SGBCC Expert Voting: HER2 Positive, BRCA Associated, Bone Modifying Therapy, Molecular Diagnosis

By Lucy 2023.10.24

The 18th St.Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, known as the "Capital of World Music", from March 15th to 18th, 2023 local time. On the last day of the conference, the highlight was the expert voting session. Oncology Frontier has compiled expert voting on the treatment of HER2 positive breast cancer, BRCA Associated treatment, Bone Modifying Therapy , oligo-metastatic disease, and molecular diagnosis topics. Additionally, a selection of these topics was presented for readers to vote on, allowing them to immerse themselves in the St.Gallen atmosphere of early breast cancer treatment decision-making.

WCLC 2023 : Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

By Peng Geng 2023.10.23

On the final day of the 2023 World Conference on Lung Cancer (WCLC) , Oncology Frontier had the privilege of interviewing Dr. Wu Yilong from Guangdong Provincial People's Hospital, Dr. Cheng Ying from Jilin Cancer Hospital, and Dr. Han Baohui from Shanghai Chest Hospital. These three experts participated in a dialogue and discussion regarding hot topics at the conference and significant clinical research. Here present the highlights of their on-site discussions.

WCLC 2023 | Dr. Liu: Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.

WCLC 2023 | Dr. Chen Haiquan: The Asian Perspective on Lung Cancer Screening

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo. On the first day, Dr. Chen Haiquan, Director of the Lung Cancer Research Center at Fudan University and Chief of Thoracic Surgery at Fudan University Affiliated Tumor Hospital, gave an important presentation. During an interview with "Oncology Frontier", Dr. Chen Haiquan shared the key points of his presentation.

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

By Peng Geng 2023.10.23

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology.

WCLC 2023 | Dr. Shi Meiqi: Treatment Strategies for EGFR Mutation and KRAS Mutation Non-Small Cell Lung Cancer

By Peng Geng 2023.10.23

The 2023 World Lung Cancer Congress (WCLC) took place at the Singapore Expo Center from September 9th to 12th. Dr. Shi Meiqi from Jiangsu Cancer Hospital presented crucial findings in a phase 1/2 clinical study at this conference (MA15.09). In an interview with " Oncology Frontier ," Dr. Shi Meiqi shared research insights, key results, and treatment strategies for KRAS mutation non-small cell lung cancer patients.